These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 29704019

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H.
    Cancer; 2017 Feb 01; 123(3):426-435. PubMed ID: 27657543
    [Abstract] [Full Text] [Related]

  • 23. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Zhang S, Zhou W, Li Y, Yu S, Xue M, Qiao Y, Jian J, Liu B, Wang D.
    Leuk Lymphoma; 2019 May 01; 60(5):1316-1319. PubMed ID: 30328750
    [No Abstract] [Full Text] [Related]

  • 24. New approaches for the detection of minimal residual disease in acute myeloid leukemia.
    van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ.
    Curr Hematol Malig Rep; 2007 May 01; 2(2):111-8. PubMed ID: 20425359
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
    Marani C, Clavio M, Grasso R, Colombo N, Guolo F, Kunkl A, Ballerini F, Giannoni L, Ghiggi C, Fugazza G, Ravetti JL, Gobbi M, Miglino M.
    Leuk Res; 2013 Dec 01; 37(12):1606-11. PubMed ID: 23891447
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
    Álvarez N, Martín A, Dorado S, Colmenares R, Rufián L, Rodríguez M, Giménez A, Carneros L, Sanchez R, Carreño G, Rapado I, Heredia Y, Martínez-López J, Barrio S, Ayala R.
    Front Immunol; 2024 Dec 01; 15():1252258. PubMed ID: 38938565
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML.
    Int J Lab Hematol; 2017 May 01; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [Abstract] [Full Text] [Related]

  • 32. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A, Gillis D, Lewis I.
    Cytometry B Clin Cytom; 2009 Mar 01; 76(2):91-101. PubMed ID: 18727068
    [Abstract] [Full Text] [Related]

  • 33. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y, Fu Y, Liu C, Sun J, Liu S, Lin H, Liu Q, Yang Y, Li Y, Su L, Gao S.
    Hematology; 2019 Dec 01; 24(1):552-558. PubMed ID: 31315553
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W, Schoch C, Haferlach T, Schnittger S.
    Crit Rev Oncol Hematol; 2005 Nov 01; 56(2):283-309. PubMed ID: 16213150
    [Abstract] [Full Text] [Related]

  • 36. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR].
    Jiang YM, Yuan H, Liu XY, Wang B, Li SJ, Wang N.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb 01; 17(1):17-22. PubMed ID: 19236739
    [Abstract] [Full Text] [Related]

  • 37. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Feb 01; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 38. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH.
    Am J Hematol; 2013 Apr 01; 88(4):318-27. PubMed ID: 23526416
    [Abstract] [Full Text] [Related]

  • 39. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L, Chen WM, Dao FT, Zhang YH, Wang YZ, Chang Y, Liu YR, Jiang Q, Zhang XH, Liu KY, Huang XJ, Qin YZ.
    Cancer Med; 2019 Sep 01; 8(12):5459-5467. PubMed ID: 31364309
    [Abstract] [Full Text] [Related]

  • 40. Should minimal residual disease guide therapy in AML?
    Paietta E.
    Best Pract Res Clin Haematol; 2015 Sep 01; 28(2-3):98-105. PubMed ID: 26590765
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.